Management of uncomplicated Chlamydia trachomatis infections in adolescents and adults: evidence reviewed for the 2006 Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines.

In April 2005, in preparation for the 2006 Centers for Disease Control and Prevention (CDC) sexually transmitted diseases (STD) treatment guidelines, the CDC convened an advisory group to examine recent abstracts and published literature addressing management of Chlamydia trachomatis infections in adolescents and adults. Key questions were posed and answered on the basis of quality of evidence and expert opinion. Clinical trials continue to demonstrate equivalent efficacy and tolerability of azithromycin and doxycycline regimens, and both remain recommended as first-line therapy in nonpregnant individuals. More data and clinical experience are available to support the efficacy, safety, and tolerability of azithromycin in pregnant women, and, in the upcoming guidelines, azithromycin will be recommended as first-line therapy for such patients. Evidence is building that expedited partner therapy (EPT), with provision of treatment or a prescription, may be just as effective as or more effective than standard partner referral in ensuring partner treatment and preventing chlamydia recurrence in women. Although there are more studies needed and barriers to be addressed before its widespread use, EPT will be recommended as an option for partner management.

[1]  J. Schillinger,et al.  Repeat Chlamydia trachomatis infection in women: analysis through a surveillance case registry in Washington State, 1993-1998. , 2000, American journal of epidemiology.

[2]  G. López,et al.  Single-dose azithromycin for Chlamydia in pregnant women. , 1998, The Journal of reproductive medicine.

[3]  E. Hook,et al.  Measured versus self-reported compliance with doxycycline therapy for chlamydia-associated syndromes: high therapeutic success rates despite poor compliance. , 1999, Sexually transmitted diseases.

[4]  M. Postma,et al.  Cost-effectiveness of partner pharmacotherapy in screening women for asymptomatic infection with Chlamydia Trachomatis. , 2001, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[5]  W. Levine,et al.  Trends in the Prevalence of Chlamydial Infections: The Impact of Community‐Wide Testing , 1997, Sexually transmitted diseases.

[6]  C. Adair,et al.  Chlamydia in Pregnancy: A Randomized Trial of Azithromycin and Erythromycin , 1998, Obstetrics and gynecology.

[7]  R. Kirby,et al.  A randomized controlled trial comparing amoxicillin and azithromycin for the treatment of Chlamydia trachomatis in pregnancy. , 2001, American journal of obstetrics and gynecology.

[8]  Gale R. Burstein,et al.  Adolescent Chlamydia Testing Practices and Diagnosed Infections in a Large Managed Care Organization , 2001, Sexually transmitted diseases.

[9]  U. P. S. T. Force.  Screening for chlamydial infection: recommendations and rationale. , 2001, American family physician.

[10]  K. Holmes,et al.  Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. , 2005, The New England journal of medicine.

[11]  G. Dimcevski,et al.  Recurrence of urogenital Chlamydia trachomatis infection evaluated by mailed samples obtained at home: 24 weeks' prospective follow up study , 2000, Sexually transmitted infections.

[12]  H. Bauer,et al.  An Observational Cohort Study of Chlamydia trachomatis Treatment in Pregnancy , 2006, Sexually transmitted diseases.

[13]  J. Fortenberry,et al.  Patient-Delivered Partner Treatment With Azithromycin to Prevent Repeated Chlamydia trachomatis Infection Among Women: A Randomized, Controlled Trial , 2003, Sexually transmitted diseases.

[14]  C. Lau,et al.  Azithromycin Versus Doxycycline for Genital Chlamydial Infections: A Meta-Analysis of Randomized Clinical Trials , 2002, Sexually transmitted diseases.

[15]  Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. , 1996 .

[16]  W. Cates,et al.  Estimates of the Incidence and Prevalence of Sexually Transmitted Diseases in the United States , 1999 .

[17]  L. Bodin,et al.  Decreasing Incidences of Gonorrhea‐ and Chlamydia‐Associated Acute Pelvic Inflammatory Disease: A 25‐Year Study From an Urban Area of Central Sweden , 1996, Sexually transmitted diseases.

[18]  J. Fortenberry,et al.  Determinants of Persistent and Recurrent Chlamydia trachomatis Infection in Young Women: Results of a Multicenter Cohort Study , 2001, Sexually transmitted diseases.

[19]  J. Fortenberry,et al.  The Prevalence of Chlamydia, Gonorrhea, and Trichomonas in Sexual Partnerships: Implications for Partner Notification and Treatment , 2005, Sexually transmitted diseases.

[20]  J. Schwartz,et al.  Doxycycline Compared with Azithromycin for Treating Women with Genital Chlamydia trachomatis Infections: An Incremental Cost-Effectiveness Analysis , 1996, Annals of Internal Medicine.

[21]  E. Hook,et al.  Compliance With Doxycycline Therapy in Sexually Transmitted Diseases Clinics , 1998, Sexually transmitted diseases.

[22]  G. Burstein,et al.  Sexually transmitted diseases treatment guidelines , 2003, Current opinion in pediatrics.

[23]  J. Peipert,et al.  A Randomized Trial of Azithromycin Versus Amoxicillin for the Treatment of Chlamydia trachomatis in pregnancy , 2001, Infectious diseases in obstetrics and gynecology.

[24]  E. Bailey,et al.  Economic Evaluation of Three Methods of Treating Urogenital Chlamydial Infections in the Emergency Department , 1999, Pharmacotherapy.

[25]  T. Farley,et al.  Patient-delivered partner treatment for male urethritis: a randomized, controlled trial. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.